Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Aug 6, 2026 · Filed Aug 10, 2026
Charles River Laboratories's SVP, Finance and CAO sold $312K of Charles River Laboratories shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$311,529
Shares × reported transaction price
1 day after results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $265.51 on Aug 6, 2026, at its 52-week high, after a 31% rise over the previous 30 trading days
52-week range $145.57 (Sep 25, 2025) to $265.51 (Aug 6, 2026), 100% of the way up, from 251 adjusted closes. 30 trading days earlier: $202.10 on Jun 24, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.0% | -0.4% | -0.6% |
| 30 days | -3.2% | -1.6% | -1.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Director sold ~$10.1M of Charles River Laboratories
Scheduled in advance